Peyronie’s disease: Past, present, future? Alan W. ShindelTom F. Lue Invited Commentary 25 November 2008 Pages: 425 - 427
The treatment of overactive bladder: A primary care provider’s perspective Matt T. Rosenberg Invited Commentary 25 November 2008 Pages: 428 - 432
Producing organs in the laboratory Mark E. FurthAnthony Atala Invited Commentary 25 November 2008 Pages: 433 - 436
A 43-year-old African American man with low-risk prostate cancer Mark Soloway Challenging Case 25 November 2008 Pages: 437 - 440
Botulinum toxin treatment for overactive bladder: Risk of urinary retention Ahmed M. ShabanMarcus J. Drake OriginalPaper 25 November 2008 Pages: 445 - 451
Augmentation cystoplasty: What are the indications? Polina ReyblatDavid A. Ginsberg OriginalPaper 25 November 2008 Pages: 452 - 458
Urothelial effects of oral agents for overactive bladder Karl-Erik AnderssonClaudius FullhaseRoberto Soler OriginalPaper 25 November 2008 Pages: 459 - 464
The effects of reformulation: Improved therapeutic index Scott MacDiarmidBobby W. Sandage JrBimal K. Malhotra OriginalPaper 25 November 2008 Pages: 465 - 471
Sexual dysfunction in women: What can urologists contribute? Irwin Goldstein OriginalPaper 25 November 2008 Pages: 475 - 482
Increasing size with penile implants Drogo K. MontagueKenneth W. Angermeier OriginalPaper 25 November 2008 Pages: 483 - 486
Penile implant infections: Prevention and treatment John J. Mulcahy OriginalPaper 25 November 2008 Pages: 487 - 491
Penile change following radical prostatectomy: Size, smooth muscle atrophy, and curve Andrew McCullough OriginalPaper 25 November 2008 Pages: 492 - 499
Testosterone and the prostate: Implications for the treatment of hypogonadal men Joshua D. HolyoakE. David CrawfordRandall B. Meacham OriginalPaper 25 November 2008 Pages: 500 - 505
Vacuum erection devices to treat erectile dysfunction and early penile rehabilitation following radical prostatectomy Craig D. ZippeGeetu Pahlajani OriginalPaper 25 November 2008 Pages: 506 - 513